Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 75

Sort by

Sort Order Select

Journal Articles

Novel Plasma Cell-Free RNA-Based Liquid Biopsy Approach for CLL

Blood (2024) 144 (Supplement 1): 3610.

https://doi.org/10.1182/blood-2024-205248

Published: 2024

Journal Articles

Use of Molecular Immune Signatures for Frontline Treatment Selection in Patients with Advanced Stage Follicular Lymphoma

Tony Z. Zhuang, Lei Feng, Dai Chihara, Chijioke Nze, Amy A. Ayers, Mansoor Noorani, James D. Ayres, Daniela E. Duenas, Kumudha Balakrishnan, Ekaterina Nesterenko, Mark Meerson, Ksenia Zornikova, Krystle Nomie, Nikita Kotlov, Nathan Fowler, Maria Alma Rodriguez, Sattva S. Neelapu, Christopher R. Flowers, Paolo Strati

Blood (2024) 144 (Supplement 1): 2982.

https://doi.org/10.1182/blood-2024-202654

Published: 2024

Journal Articles

Machine Learning-Based Approach to Improve Classification and Diagnostics of Peripheral T-Cell Lymphomas

Anastasia Sobol, Stepan Kuznetsov, Anton Kremlev, Giorgio Inghirami, Nathan Fowler, Nikita Kotlov, Anastasia Nikitina

Blood (2024) 144 (Supplement 1): 1593.

https://doi.org/10.1182/blood-2024-201683

Published: 2024

Journal Articles

Comprehensive Analysis of Malignant B-Cell Receptors Provides Insights into B-Cell Lymphoma Pathogenesis

Evgeniia Alekseeva, Vasiliy Minkov, Alexander Nesmelov, Mikhail Shugay, Nathan Fowler, Alexander Bagaev, Nikita Kotlov

Blood (2024) 144 (Supplement 1): 4341.

https://doi.org/10.1182/blood-2024-201650

Published: 2024

Journal Articles

Preliminary Analysis of an Ongoing Phase II Study of Response-Adapted Therapy with Copanlisib and Rituximab for Untreated Follicular Lymphoma

Blood (2023) 142 (Supplement 1): 1676.

https://doi.org/10.1182/blood-2023-185038

Published: 2023

Journal Articles

Clinical Outcomes of Patients with Relapsed/Refractory Follicular Lymphoma Treated with Tisagenlecleucel: Phase 2 Elara 3-Year Follow-up

Blood (2023) 142 (Supplement 1): 601.

https://doi.org/10.1182/blood-2023-180936

Published: 2023

Journal Articles

Genomic and Transcriptomic Profiles of Blastoid and Pleomorphic Mantle Cell Lymphoma Are Distinct from Classic Histology Mantle Cell Lymphoma

Preetesh Jain, Holly A Hill, Chi Young Ok, Alexander Nesmalov, Vitaly Segodin, Dmitry Tabakov, Nikita Kotlov, Pavel Zemskiy, Eleonora Belykh, Krystle Nomie, Ahmed Fetooh, Rashmi Kanagal-Shamanna, Fatima Z Jelloul, Guilin Tang, Francisco Vega, Nathan Fowler, Christopher R. Flowers, Michael L. Wang

Blood (2023) 142 (Supplement 1): 3001.

https://doi.org/10.1182/blood-2023-181319

Published: 2023

Journal Articles

Long Term Durable Responses in Relapsed/Refractory (r/r) ALL, DLBCL, and FL Patients Treated with Tisagenlecleucel and Its Association with Persistence of CAR T-Cells

Rakesh Awasthi, Edward Waldron, Stephan Grupp, Michael A. Pulsipher, Peter Bader, Stephen J Schuster, Richard T Maziarz, Edmund K. Waller, Ulrich Jaeger, Catherine Thieblemont, Martin Dreyling, Nathan Fowler, Harald Jakob Maier, Jennifer Willert

Blood (2023) 142 (Supplement 1): 4872.

https://doi.org/10.1182/blood-2023-181663

Published: 2023

Journal Articles

Test-the-Test: Clinical Utility of Comprehensive Whole Exome Sequencing and RNA-Seq for Patients with Lymphoma

Dai Chihara, Kumudha Balakrishnan, Gita Masand, Anna Novokreshchenova, Alexander Bagaev, Nikita Kotlov, Ekaterina Postovalova, Eduardo Shugaev-Mendosa, Yuliya Gracheva, Anna Love, Krystle Nomie, Nathan Fowler, Christopher R. Flowers, Jason Westin

Blood (2023) 142 (Supplement 1): 7155.

https://doi.org/10.1182/blood-2023-189426

Published: 2023

Journal Articles

A Novel Comprehensive Tumor-Informed Plasma cfDNA Assay to Monitor Minimal Residual Disease for Hematological and Solid Malignancies

Anastasiya Yudina, Anastasiya Danchurova, Lolita Alekseeva, Aleksei Efremov, Sergei Starikov, Danielle Sookiasian, Ekaterina Nuzhdina, Svetlana Podsvirova, Madison Chasse, Tori Conroy, Noel English, Dmitry Tabakov, Sheila T. Yong, Artur Baisangurov, Cagdas Tazearslan, Nathan Fowler, Alexander Bagaev

Blood (2023) 142 (Supplement 1): 3644.

https://doi.org/10.1182/blood-2023-174909

Published: 2023

Journal Articles

Kinase inhibitors in CLL: drawing the roadmap

Nathan Fowler

Blood (2021) 137 (20): 2717–2719.

https://doi.org/10.1182/blood.2020010052

Published: 2021

Journal Articles

BCL-2 inhibition in follicular lymphoma: can we tip the scales?

Nathan Fowler

Blood (2020) 136 (23): 2598–2600.

https://doi.org/10.1182/blood.2020008194

Published: 2020

Journal Articles

Ublituximab and umbralisib in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia

Matthew Lunning, Julie Vose, Loretta Nastoupil, Nathan Fowler, Jan A. Burger, William G. Wierda, Marshall T. Schreeder, Tanya Siddiqi, Christopher R. Flowers, Jonathon B. Cohen, Peter Sportelli, Hari P. Miskin, Michael S. Weiss, Susan O’Brien

Blood (2019) 134 (21): 1811–1820.

https://doi.org/10.1182/blood.2019002118

Published: 2019

Includes: Supplemental data

Journal Articles

An Integrated Safety Analysis of the Next Generation PI3Kδ Inhibitor Umbralisib (TGR-1202) in Patients with Relapsed/Refractory Lymphoid Malignancies

Blood (2017) 130 (Supplement 1): 4037.

https://doi.org/10.1182/blood.V130.Suppl_1.4037.4037

Published: 2017

Journal Articles

Safety and Activity of Lenalidomide and Rituximab in Previously Untreated Marginal Zone Lymphoma: Subgroup Analysis and Long-Term Follow-up of an Open-Label Phase II Trial

Melody R Becnel, MD, Loretta Nastoupil, MD, R. Eric Davis, MD, F. B. Hagemeister, MD, Michelle A. Fanale, MD, Luis Fayad, MD, Jason R. Westin, MD, Michael Wang, BS, Yasuhiro Oki, MD, Linda Claret, Sheryl G Forbes, Lei Feng, MS, Felipe Samaniego, MD, Sattva S. Neelapu, MD, Nathan Fowler, MD

Blood (2017) 130 (Supplement 1): 4040.

https://doi.org/10.1182/blood.V130.Suppl_1.4040.4040

Published: 2017

Journal Articles

The Risk of Central Nervous System (CNS) Relapses in Patients with Peripheral T-Cell Lymphoma

Dai Chihara, MD PhD, Michelle A Fanale, MD, Roberto N. Miranda, MD, Mansoor Noorani, Jason R. Westin, MD, Loretta J. Nastoupil, MD, Fredrick B. Hagemeister, MD, Luis E. Fayad, MD, Jorge E. Romaguera, MD, Felipe Samaniego, MD, Francesco Turturro, MD, Hun Ju Lee, MD, Sattva S. Neelapu, MD, Alma Rodriguez, MD, Michael Wang, MD, Nathan Fowler, MD, L. Jeffrey Medeiros, MD, Richard Eric Davis, MD, Yasuhiro Oki, MD

Blood (2016) 128 (22): 4153.

https://doi.org/10.1182/blood.V128.22.4153.4153

Published: 2016

Journal Articles

Analyzing Patient Characteristics Who Received (DA) EPOCH-R for High Risk Diffuse Large B-Cell Lymphoma: MD Anderson Cancer Center Experience

Blood (2016) 128 (22): 4208.

https://doi.org/10.1182/blood.V128.22.4208.4208

Published: 2016

Journal Articles

Characteristics, Outcome and Pattern of Mutations in Patients with Follicular Lymphoma Who Progressed on BTK Inhibitors (Ibrutinib and acalabrutinib)

Preetesh Jain, MBBS,MDDM,PhD, Rashmi Kanagal-Shamanna, MD, Francis San Lucas, Michael Wang, MD, Jorge E. Romaguera, MD, Luis E. Fayad, MD, Yasuhiro Oki, MD, Jason R. Westin, MD, Jeffrey Medeiros, MD, Nathan Fowler, MD

Blood (2016) 128 (22): 2975.

https://doi.org/10.1182/blood.V128.22.2975.2975

Published: 2016

Journal Articles

Ibrutinib Combined with Rituximab in Treatment-Naive Patients with Follicular Lymphoma: Arm 1 + Arm 2 Results from a Multicenter, Open-Label Phase 2 Study

Nathan Fowler, MD, Loretta Nastoupil, MD, Sven de Vos, MD PhD, Mark Knapp, MD, Ian W. Flinn, MD PhD, Robert W Chen, MD, Ranjana H Advani, MD, Sumeet Bhatia, MD, Peter Martin, MD, Raul Mena, MD, Samuel Suzuki, MS, MBA, Darrin M. Beaupre, MD PhD, Jutta K. Neuenburg, MD PhD, M. Lia Palomba, MD

Blood (2016) 128 (22): 1804.

https://doi.org/10.1182/blood.V128.22.1804.1804

Published: 2016

Journal Articles

The Final Report of a Phase I/II Study of Panobinostat in Combination with ICE (Ifosfamide, Carboplatin and Etoposide) in Patients (pts) with Relapsed or Refractory (R/R) Classical Hodgkin Lymphoma (cHL)

Bei Hu, MD, Anas Younes, MD, Linda Claret, Lei Feng, MS, Jason R. Westin, MD, Nathan Fowler, MD, Sattva Neelapu, MD, Fredrick B. Hagemeister, MD, Maria Alma Rodriguez, MD, Felipe Samaniego, MD, Luis E. Fayad, MD, Loretta J. Nastoupil, MD, Amanda R Copeland, RN, MSN, CNS, Michelle A Fanale, MD, Yasuhiro Oki, MD

Blood (2016) 128 (22): 1833.

https://doi.org/10.1182/blood.V128.22.1833.1833

Published: 2016

NARROW

Novel Plasma Cell-Free RNA-Based Liquid Biopsy Approach for CLL

Use of Molecular Immune Signatures for Frontline Treatment Selection in Patients with Advanced Stage Follicular Lymphoma

Machine Learning-Based Approach to Improve Classification and Diagnostics of Peripheral T-Cell Lymphomas

Comprehensive Analysis of Malignant B-Cell Receptors Provides Insights into B-Cell Lymphoma Pathogenesis

Preliminary Analysis of an Ongoing Phase II Study of Response-Adapted Therapy with Copanlisib and Rituximab for Untreated Follicular Lymphoma

Clinical Outcomes of Patients with Relapsed/Refractory Follicular Lymphoma Treated with Tisagenlecleucel: Phase 2 Elara 3-Year Follow-up

Genomic and Transcriptomic Profiles of Blastoid and Pleomorphic Mantle Cell Lymphoma Are Distinct from Classic Histology Mantle Cell Lymphoma

Long Term Durable Responses in Relapsed/Refractory (r/r) ALL, DLBCL, and FL Patients Treated with Tisagenlecleucel and Its Association with Persistence of CAR T-Cells

Test-the-Test: Clinical Utility of Comprehensive Whole Exome Sequencing and RNA-Seq for Patients with Lymphoma

A Novel Comprehensive Tumor-Informed Plasma cfDNA Assay to Monitor Minimal Residual Disease for Hematological and Solid Malignancies

Kinase inhibitors in CLL: drawing the roadmap

BCL-2 inhibition in follicular lymphoma: can we tip the scales?

Ublituximab and umbralisib in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia

An Integrated Safety Analysis of the Next Generation PI3Kδ Inhibitor Umbralisib (TGR-1202) in Patients with Relapsed/Refractory Lymphoid Malignancies

Safety and Activity of Lenalidomide and Rituximab in Previously Untreated Marginal Zone Lymphoma: Subgroup Analysis and Long-Term Follow-up of an Open-Label Phase II Trial

The Risk of Central Nervous System (CNS) Relapses in Patients with Peripheral T-Cell Lymphoma

Analyzing Patient Characteristics Who Received (DA) EPOCH-R for High Risk Diffuse Large B-Cell Lymphoma: MD Anderson Cancer Center Experience

Characteristics, Outcome and Pattern of Mutations in Patients with Follicular Lymphoma Who Progressed on BTK Inhibitors (Ibrutinib and acalabrutinib)

Ibrutinib Combined with Rituximab in Treatment-Naive Patients with Follicular Lymphoma: Arm 1 + Arm 2 Results from a Multicenter, Open-Label Phase 2 Study

The Final Report of a Phase I/II Study of Panobinostat in Combination with ICE (Ifosfamide, Carboplatin and Etoposide) in Patients (pts) with Relapsed or Refractory (R/R) Classical Hodgkin Lymphoma (cHL)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only